Globus Medical (GMED) Competitors $52.60 -0.03 (-0.06%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$52.65 +0.05 (+0.09%) As of 08/1/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GMED vs. STE, PODD, BAX, HOLX, MASI, TFX, ITGR, ATEC, ATRC, and IARTShould you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), AtriCure (ATRC), and Integra LifeSciences (IART). These companies are all part of the "health care equipment" industry. Globus Medical vs. Its Competitors STERIS Insulet Baxter International Hologic Masimo Teleflex Integer Alphatec AtriCure Integra LifeSciences Globus Medical (NYSE:GMED) and STERIS (NYSE:STE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is GMED or STE more profitable? STERIS has a net margin of 11.26% compared to Globus Medical's net margin of 7.39%. STERIS's return on equity of 14.21% beat Globus Medical's return on equity.Company Net Margins Return on Equity Return on Assets Globus Medical7.39% 10.52% 8.56% STERIS 11.26%14.21%9.13% Which has higher valuation & earnings, GMED or STE? STERIS has higher revenue and earnings than Globus Medical. STERIS is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobus Medical$2.52B2.83$102.98M$1.3439.25STERIS$5.46B4.08$614.64M$6.2036.56 Do insiders and institutionals believe in GMED or STE? 95.2% of Globus Medical shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 18.5% of Globus Medical shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, GMED or STE? Globus Medical has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Does the media prefer GMED or STE? In the previous week, Globus Medical had 1 more articles in the media than STERIS. MarketBeat recorded 17 mentions for Globus Medical and 16 mentions for STERIS. STERIS's average media sentiment score of 1.23 beat Globus Medical's score of 0.81 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive STERIS 10 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GMED or STE? Globus Medical currently has a consensus price target of $90.09, indicating a potential upside of 71.28%. STERIS has a consensus price target of $270.33, indicating a potential upside of 19.25%. Given Globus Medical's higher possible upside, analysts plainly believe Globus Medical is more favorable than STERIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Globus Medical 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.62STERIS 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummarySTERIS beats Globus Medical on 9 of the 16 factors compared between the two stocks. Get Globus Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMED vs. The Competition Export to ExcelMetricGlobus MedicalMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$7.13B$6.76B$5.49B$20.65BDividend YieldN/A1.32%4.73%3.67%P/E Ratio39.2520.9428.7829.03Price / Sales2.8354.12372.2066.13Price / Cash7.9020.5035.4522.84Price / Book1.734.468.274.43Net Income$102.98M$174.54M$3.25B$994.22M7 Day Performance-3.39%-5.27%-3.70%-3.39%1 Month Performance-13.11%-3.94%4.34%-2.09%1 Year Performance-23.86%8.26%25.90%10.09% Globus Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMEDGlobus Medical4.8584 of 5 stars$52.60-0.1%$90.09+71.3%-24.9%$7.13B$2.52B39.255,300News CoverageUpcoming EarningsSTESTERIS4.775 of 5 stars$226.44-1.7%$270.33+19.4%-5.9%$22.67B$5.46B36.5217,787News CoveragePositive NewsUpcoming EarningsDividend IncreasePODDInsulet4.6076 of 5 stars$292.27+0.7%$321.00+9.8%+44.4%$20.42B$2.07B52.573,900News CoveragePositive NewsUpcoming EarningsBAXBaxter International4.7941 of 5 stars$28.51-2.4%$36.38+27.6%-39.0%$14.99B$10.64B-25.9238,000Trending NewsEarnings ReportAnalyst ForecastHOLXHologic4.8658 of 5 stars$65.69-1.2%$77.33+17.7%-19.3%$14.82B$4.03B27.727,063Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMASIMasimo3.6862 of 5 stars$162.18-1.5%$191.60+18.1%+43.4%$8.93B$2.09B-17.695,600Positive NewsUpcoming EarningsTFXTeleflex4.7359 of 5 stars$115.64-1.3%$159.63+38.0%-50.9%$5.18B$3.05B36.4814,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastITGRInteger3.3619 of 5 stars$108.02-0.5%$140.25+29.8%-8.2%$3.79B$1.72B47.5911,000ATECAlphatec4.2333 of 5 stars$11.19+3.4%$18.13+62.0%+107.4%$1.58B$611.56M-9.73700Trending NewsEarnings ReportAnalyst ForecastGap UpATRCAtriCure3.4425 of 5 stars$33.22+5.5%$50.67+52.5%+63.5%$1.56B$465.31M-41.011,300News CoverageEarnings ReportAnalyst ForecastHigh Trading VolumeIARTIntegra LifeSciences4.2481 of 5 stars$13.10-0.1%$18.63+42.2%-50.0%$1.02B$1.61B-34.474,396Trending NewsEarnings Report Related Companies and Tools Related Companies STERIS Alternatives Insulet Alternatives Baxter International Alternatives Hologic Alternatives Masimo Alternatives Teleflex Alternatives Integer Alternatives Alphatec Alternatives AtriCure Alternatives Integra LifeSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GMED) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globus Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
